Levolin Plus Jr Expectorant is a combination pharmaceutical formulation containing Ambroxol (15 mg), Levosalbutamol (0.5 mg), and Guaifenesin (50 mg), designed to provide effective relief in pediatric patients with respiratory conditions characterized by mucus hypersecretion and bronchospasm. Ambroxol acts as a mucolytic agent by breaking down and thinning viscous mucus, facilitating easier expectoration and improving airway clearance. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides bronchodilation by relaxing bronchial smooth muscle, thereby alleviating bronchospasm and improving airflow obstruction. Guaifenesin serves as an expectorant, promoting the hydration of respiratory tract secretions, which enhances mucus clearance and reduces cough frequency. The synergistic action of these active ingredients makes Levolin Plus Jr Expectorant suitable for managing acute and chronic respiratory conditions such as bronchitis, asthma exacerbations, and other obstructive airway diseases in children. The formulation is intended for oral administration and should be used under medical supervision, with dosage adjusted according to age and clinical response. Caution is advised in patients with hypersensitivity to any component, cardiovascular disorders, or hyperthyroidism. This combination therapy aims to improve respiratory function by reducing mucus viscosity, easing expectoration, and relieving bronchoconstriction, thereby enhancing patient comfort and recovery.